The 2010 ASCO Annual Meeting has begun in Chicago on June 4 and will last until June 8 2010 (so do not try to reach your oncologist until then).
2010 ASCO Annual Meeting Abstracts are avail for the viewing here:
http://abstract.asco.org/index20100505.html
2010 ASCO Annual Meeting
-
Fictional
Drug Update from ASCO - Crizotinib, Ipilimumab, Vandetamib
The biggest news at ASCO besides the ALB 109564 mentioned in the other thread and Cediranib, here are drugs that have potential in ASPS and look as if they may be approved in the next year or so:
PF02341066 (crizotinib) - Met inhibitor / EML-ALK inhibitor (Non small cell lung cancer)
Ipilimumab (CTLA-4) - metastatic melanoma - may boost your body's immune attack against cancer (Anthony was on this after GVAX)
Vandetanib (Zactima) - medullary thyroid CA - VEGFR blocker (blocks VEGFR2 - interesting as this is Cediranib's difference vs. Sutent), as well as inhibitor of RET (present in ASPS), and EGFR (not thought to be important in ASPS)
PF02341066 (crizotinib) - Met inhibitor / EML-ALK inhibitor (Non small cell lung cancer)
Ipilimumab (CTLA-4) - metastatic melanoma - may boost your body's immune attack against cancer (Anthony was on this after GVAX)
Vandetanib (Zactima) - medullary thyroid CA - VEGFR blocker (blocks VEGFR2 - interesting as this is Cediranib's difference vs. Sutent), as well as inhibitor of RET (present in ASPS), and EGFR (not thought to be important in ASPS)